For the first time, a study from the University of British Columbia associated medicines widely used to treat obesity with a increased risk of stomach paralysis.
The study revealed that patients face high risks of pancreatitis and intestinal obstruction, although such effects were already listed in the leaflets of these drugs. medicines.
see more
Legs, why do I want you? Running generates the same effects as…
Drinking orange juice for breakfast can be DANGEROUS, warns…
These results, recently published in the Journal of the American Medical Association, draw attention to a additional concern: adverse effects were observed in patients without diabetes, but who were using the drugs to lose weight.
Medicines, initially developed to treat type 2 diabetes, have also been prescribed to help with weight loss.
Its action involves inducing insulin production, inhibiting sugar production in the liver and promoting the feeling of satiety.
Thus, they play a dual role, seeking to control blood sugar levels in diabetics and helping with weight reduction in overweight individuals.
However, recent results highlight the need for a more comprehensive evaluation of its side effects, especially in relation to gastrointestinal complications.
The research was based on the prescriptions of 16 million patients in the United States, who were prescribed one of two most popular medications in the GLP-1 agonist class — semaglutide and liraglutide — during the period between 2006 and 2020.
According to researchers, people taking such medications to treat type 2 diabetes were not included, as the research focused specifically on patients who used them to lose Weight.
(Image: disclosure)
Researchers conducted an analysis of patients' medical records to determine how many of them have developed gastrointestinal problems, including pancreatitis, bladder obstruction, gastroparesis, and biliary.
The medical records were then compared with those of other patients who were using the bupropion-naltrexone medication, which belongs to another drug class and is also used to weight loss.
The results revealed that patients who took medications from the GLP-1 agonist class had a nine times greater risk of developing pancreatitis compared to those who used the medicine bupropion-naltrexone.
The finding, therefore, points to a significantly elevated risk associated with these medications with regards to that specific condition.
At Trezeme Digital, we understand the importance of effective communication. We know that every word matters, which is why we strive to deliver content that is relevant, engaging and personalized to meet your needs.